Lilly’s Taltz scrapes win against Humira in psoriatic arthritisEli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been Share XLilly’s Taltz scrapes win against Humira in psoriatic arthritishttps://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/
Boehringer settles Humira lawsuit, joins biosimilar queue in USBoehringer Ingelheim was the last man standing among challengers to AbbVie’s patents on immunology blockbuster Humira but has Share XBoehringer settles Humira lawsuit, joins biosimilar queue in UShttps://pharmaphorum.com/news/boehringer-settles-humira-lawsuit-joins-biosimilar-queue-in-us/
AbbVie’s JAK inhibitor upadacitinib gets Priority ReviewAbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Share XAbbVie’s JAK inhibitor upadacitinib gets Priority Reviewhttps://pharmaphorum.com/news/abbvies-jak-inhibitor-upadacitinib-gets-priority-review/
AbbVie wobbles as biosimilars bite HumiraAbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly Share XAbbVie wobbles as biosimilars bite Humirahttps://pharmaphorum.com/news/abbvie-wobbles-as-biosimilars-bite-humira/
2018 in review: Humira biosimilars arrive in EuropeThe emergence this year of Humira biosimilars in Europe followed a period of sustained momentum around the cheaper Share X2018 in review: Humira biosimilars arrive in Europehttps://pharmaphorum.com/views-analysis-sales-marketing/2018-review-humira-biosimilars-europe/
AbbVie, Pfizer reach licencing agreement for biosimilar HumiraAbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries Share XAbbVie, Pfizer reach licencing agreement for biosimilar Humirahttps://pharmaphorum.com/news/abbvie-pfizer-reach-licencing-agreement-for-biosimilar-humira/
Has the NHS joined the biosimilars revolution?Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Share XHas the NHS joined the biosimilars revolution?https://pharmaphorum.com/oncology/nhs-joined-biosimilar-revolution/
FDA approves biosimilar of blockbuster HumiraA Humira biosimilar, produced by drug maker Sandoz, has been given the green light from the US Food Share XFDA approves biosimilar of blockbuster Humirahttps://pharmaphorum.com/news/fda-approves-biosimilar-blockbuster-humira/
AbbVie braces for impact of Humira biosimilars in EuropeAbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European Share XAbbVie braces for impact of Humira biosimilars in Europehttps://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/
